The Food Safety and Standards Authority of India (FSSAI) has issued notices to Nestle India and Zydus Wellness regarding misleading claims on certain food products. The regulator has asked both companies to provide scientific proof to support their advertisements and product claims.
- FSSAI issued notices to Nestle India for claims on Lactogen Pro 1 Powder and Nan Excella Pro Stage 1.
- Zydus Wellness received a notice over claims on its Complan product.
- The companies must submit scientific substantiation for their claims within a stipulated period.
- Shares of Nestle India and Zydus Wellness fell following the notices.
What claims did Nestle India make that led to the FSSAI notices?
FSSAI issued a notice to Nestle India for claims on two products: Lactogen Pro 1 Powder and Nan Excella Pro Stage 1. For Lactogen Pro 1 Powder, the company claimed that it "contains Whey Protein, which is a part of milk protein that is easy to digest." The regulator asked Nestle India to provide scientific evidence supporting this claim.
Regarding Nan Excella Pro Stage 1, Nestle claimed that "5 HMOs help support the normal immune system." FSSAI considered this claim non-compliant because it implies the product supports the immune system, which is prohibited unless specifically allowed under regulations. The claim "contains whey protein" on the packaging was also questioned, and Nestle was asked to substantiate it scientifically.
What issues did FSSAI find with Zydus Wellness's Complan product?
FSSAI issued a notice to Zydus Wellness over misleading claims on its Complan product. The product label showed images of children and included claims such as "2X Faster Growth," "Supports Concentration and Memory," and "Pro Immunity+ 34 Vital Nutrients." These claims violated the FSS (Advertising and Claims) Regulations, 2018. Additionally, the advertisement claim "growth comes in 4 flavors" was also found to be in violation. Zydus Wellness has been asked to provide scientific justification for these claims and explain why action should not be taken against the company.
How did the stock market react to these notices?
Following the FSSAI notices, shares of Nestle India and Zydus Wellness declined. On October 22, 2026, Nestle India's shares fell by 2.43% to ₹1,194.10 on the NSE, while Zydus Wellness shares dropped by 1.60% to ₹484.15.
What has been the response from Nestle India?
A Nestle India spokesperson stated that the FSSAI's recent post reiterated points from an earlier post dated September 18 regarding product labels. The company has already submitted a detailed response to the regulator on these matters.
What are the next steps for the companies involved?
Both Nestle India and Zydus Wellness have been directed by FSSAI to submit scientific evidence supporting their product claims within the stipulated time. They must also explain why legal action should not be initiated under the Food Safety and Standards Act, 2006. Failure to comply may result in further regulatory action.
